Growth of community-based immunotherapy treatment in the Veterans Health Administration

• Published in: Cancer medicine (Malden, MA) MA), 2023-09, Vol.12 (17), p.18110-18119
• Main Authors: Price, Megan Ellis, Gordon, Sarah, Emmitt, Caroline, Ndugga, Nambi, Kabdiyeva, Aigerim, Mull, Hillary, Pizer, Steven, Garrido, Melissa M
• Format: Article
• Language: English
• Subjects: cancer management; Cancer therapies; Chemotherapy; Chi-square test; clinical guidelines; clinical management; Comorbidity; Costs; Drugs; Head & neck cancer; Hospitals; Immunotherapy; Mann-Whitney U test; Medicare; Patients; Pharmacy; risk assessment; statistical methods
• ISSN: 2045-7634; 2045-7634
• DOI: 10.1002/cam4.6372

The MISSION and CHOICE Acts expanded the Veterans Health Administration's (VA) capacity to purchase immunotherapy services for VA patients from community-based providers. Our objective was to identify predictors of community-based immunotherapy treatment, and assess differences in cost and utilization across community treatment settings METHODS: We examined claims for 21,257 patients who started immunotherapy treatment between 2015 and 2020. We assessed growth in VA community-based immunotherapy care, predictors of community-based immunotherapy treatment using multivariable logistic regression based on patients' sociodemographic and clinical characteristics. We compared utilization and costs among those who received community-based immunotherapy services in hospital outpatient departments (HOPDs) versus physician office settings (POs). The proportion of community-based immunotherapy in the VA increased from 5.3% in 2015 to 32.1% in 2020, with total annual costs of immunotherapy growing from $6.1 million to $187 million. Older, married, and rural patients and those with more comorbidities were more likely than younger, single, or urban patients to be treated in the community. Black patients were more likely to be treated in the VA. Respiratory Cancer was the most common cancer type in both settings. Among community immunotherapy patients, we observed no meaningful differences in the number of units administered, the unit drug costs, or the cost per immunotherapy visit between POs and HOPDs. Drug costs did not differ widely across HOPDs and POs among VA patients who receive community-based immunotherapy.